GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi PharmaTech (Cayman) Inc (FRA:3W11) » Definitions » PE Ratio
中文

WuXi PharmaTech (Cayman) (FRA:3W11) PE Ratio

: 40.24 (As of Today)
View and export this data going back to . Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-23), WuXi PharmaTech (Cayman)'s share price is €41.49. WuXi PharmaTech (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was €1.03. Therefore, WuXi PharmaTech (Cayman)'s PE Ratio for today is 40.24.


The historical rank and industry rank for WuXi PharmaTech (Cayman)'s PE Ratio or its related term are showing as below:

FRA:3W11' s PE Ratio Range Over the Past 10 Years
Min: 6.67   Med: 18.83   Max: 103.94
Current: 40.28


During the past 12 years, the highest PE Ratio of WuXi PharmaTech (Cayman) was 103.94. The lowest was 6.67. And the median was 18.83.


FRA:3W11's PE Ratio is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 31.3 vs FRA:3W11: 40.28

WuXi PharmaTech (Cayman)'s Earnings per Share (Diluted) for the three months ended in Sep. 2015 was €0.19. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was €1.03.

As of today (2024-04-23), WuXi PharmaTech (Cayman)'s share price is €41.49. WuXi PharmaTech (Cayman)'s EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2015 was €1.02. Therefore, WuXi PharmaTech (Cayman)'s PE Ratio without NRI for today is 40.56.

During the past 12 years, WuXi PharmaTech (Cayman)'s highest PE Ratio without NRI was 102.94. The lowest was 6.62. And the median was 17.91.

WuXi PharmaTech (Cayman)'s EPS without NRI for the three months ended in Sep. 2015 was €0.19. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2015 was €1.02.

During the past 12 months, WuXi PharmaTech (Cayman)'s average EPS without NRI Growth Rate was -23.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 13.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 14.50% per year.

During the past 12 years, WuXi PharmaTech (Cayman)'s highest 3-Year average EPS without NRI Growth Rate was 330.90% per year. The lowest was 0.00% per year. And the median was 15.70% per year.

WuXi PharmaTech (Cayman)'s EPS (Basic) for the three months ended in Sep. 2015 was €0.19. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2015 was €1.04.


WuXi PharmaTech (Cayman) PE Ratio Historical Data

The historical data trend for WuXi PharmaTech (Cayman)'s PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi PharmaTech (Cayman) Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.29 10.34 12.78 24.35 21.46

WuXi PharmaTech (Cayman) Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.51 21.46 24.56 29.57 36.34

Competitive Comparison

For the Diagnostics & Research subindustry, WuXi PharmaTech (Cayman)'s PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi PharmaTech (Cayman) PE Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi PharmaTech (Cayman)'s PE Ratio distribution charts can be found below:

* The bar in red indicates where WuXi PharmaTech (Cayman)'s PE Ratio falls into.



WuXi PharmaTech (Cayman) PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

WuXi PharmaTech (Cayman)'s PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=41.49/1.031
=40.24

WuXi PharmaTech (Cayman)'s Share Price of today is €41.49.
WuXi PharmaTech (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


WuXi PharmaTech (Cayman)  (FRA:3W11) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


WuXi PharmaTech (Cayman) PE Ratio Related Terms

Thank you for viewing the detailed overview of WuXi PharmaTech (Cayman)'s PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi PharmaTech (Cayman) (FRA:3W11) Business Description

Traded in Other Exchanges
N/A
Address
WuXi PharmaTech (Cayman) Inc was incorporated on March 16, 2007 and commenced operations and began offering pharmaceutical and biotechnology R&D outsourcing services in 2001. The Company is a pharmaceutical, biotechnology and medical device R&D services company, with operations in China and the United States. It provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers, which includes pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its customers in shortening the cycle and lowering the cost of pharmaceutical and medical device R&D by providing cost-effective and efficient outsourcing solutions. Its primary China-based facilities include 1,127,000 square feet of facilities in the China (Shanghai) Pilot Free Trade Zone used for synthetic chemistry, biology, medicinal chemistry, DMPK, formulation, analytical development, manufacturing process chemistry, research manufacturing, bioanalytical services, genomics, and biologics drug discovery and development; an R&D center in Tianjin engaged in synthetic chemistry and medicinal chemistry; a facility in Wuhan providing services in synthetic chemistry and medicinal chemistry; a small-scale cGMP clinical manufacturing facility and a large-scale cGMP commercial manufacturing plant in the Jinshan district of Shanghai; a large-scale non-GMP manufacturing plant in Changzhou; a preclinical toxicology facility in Suzhou; a laboratory for manufacturing research reagents in Suzhou; and a biologics manufacturing facility in Wuxi. It also offers services in biologics and medical device testing in three FDA-registered facilities in the United States. The Company has two segments: Laboratory services and Manufacturing services. Laboratory services are provided for pharmaceutical, biotechnology and medical device companies. China-based laboratory services for pharmaceutical and biotechnology companies include services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics. U.S.-based laboratory services include testing services for biologics, medical devices, and combination products. Manufacturing services include the development of manufacturing processes and the production of intermediates and active pharmaceutical ingredients, or APIs, for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologics. The Company offers testing and development services to ensure that a medical device is manufactured, packaged and sterilized in accordance with GMP guidelines. Its in vivo and in vitro toxicology testing includes biocompatibility or safe

WuXi PharmaTech (Cayman) (FRA:3W11) Headlines

No Headlines